fbpx
close read more

Our Research & Development

A word from…

CLAUDE BERTRAND, Executive Vice President Research & Development

To enable Servier to achieve its transformation objectives by 2025, R&D has developed an initial three-year action plan. The idea is to discover and develop new medicines where patient needs are greatest.

Servier organizes its R&D in 4 therapeutic areas where it has extensive know-how and renowned expertise and in which there are high unmet patient needs: oncology, neuroscience, immuno-inflammatory diseases, as well as cardiovascular and metabolic diseases.

R&D key figures

+ than 20 %

of revenue from brand-name medicines invested in R&D each year

+ than 50 %

of the Servier global R&D budget*  dedicated to researching cancer treatments

* brand-name activity

+ than 40

active alliances worldwide

Symphogen Focus, subsidiary of the Servier Group

Founded in 2000 and based in Denmark, Symphogen is a biotech company that has developed an efficient discovery and research platform that can rapidly identify high quality monoclonal and bi-specific antibodies supported by early development capabilities with strong in vitro and in vivo capacities across oncology and immuno-oncology. Symphogen is organized as a combined project and line organization with various research, pre-clinical, CMC (Chemistry, Manufacturing and Control), clinical and regulatory departments.

As part of the acquisition by Servier, Symphogen becomes the antibody center of excellence of the Group as its platform can deliver antibodies with unique functionalities providing best or first in class potential.

READ MORE →

Last news

News
23/06/2022
Meeting the challenge of adherence: a Servier study presented at the ESH 2022 Annual Meeting!
News
15/06/2022
Appointment of Angelo Paci, Oncology & Immuno-Oncology Program Leader
News
01/06/2022
Patient associations’ perception of pharmaceutical companies: Servier is making progress!